Literature DB >> 16503733

STAT3 as a therapeutic target in head and neck cancer.

Rebecca J Leeman1, Vivian Wai Yan Lui, Jennifer Rubin Grandis.   

Abstract

The signal transducer and activator of transcription (STAT) proteins relay signals from cytokine receptors and receptor tyrosine kinases on the cell surface to the nucleus, where they affect the transcription of genes involved in normal cell functions, including growth, apoptosis and differentiation. STAT3 has been found to be constitutively active in head and neck squamous cell carcinoma (HNSCC) as well as in other epithelial malignancies. In HNSCC, STAT3 alters the cell cycle, prevents apoptosis, and mediates the proliferation and survival of tumour cells. Several therapeutic approaches are being developed to target STAT3, including molecules that block either dimerisation or DNA binding by STAT3, strategies to decrease STAT3 expression and drugs that inhibit STAT3 function. Strategies that block STAT3 may prove efficacious for cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16503733     DOI: 10.1517/14712598.6.3.231

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  104 in total

Review 1.  Molecular parameters of head and neck cancer metastasis.

Authors:  Sanjay L Bhave; Theodoras N Teknos; Quintin Pan
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2011       Impact factor: 1.807

2.  Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma.

Authors:  Makoto Adachi; Caixia Cui; Cristina T Dodge; Mihir K Bhayani; Stephen Y Lai
Journal:  Oral Oncol       Date:  2012-07-06       Impact factor: 5.337

3.  HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines.

Authors:  Paul A Johnston; Malabika Sen; Yun Hua; Daniel P Camarco; Tong Ying Shun; John S Lazo; Gabriela Mustata Wilson; Lynn O Resnick; Matthew G LaPorte; Peter Wipf; Donna M Huryn; Jennifer R Grandis
Journal:  Assay Drug Dev Technol       Date:  2015-09       Impact factor: 1.738

4.  Production of Uniform 3D Microtumors in Hydrogel Microwell Arrays for Measurement of Viability, Morphology, and Signaling Pathway Activation.

Authors:  Manjulata Singh; David A Close; Shilpaa Mukundan; Paul A Johnston; Shilpa Sant
Journal:  Assay Drug Dev Technol       Date:  2015-08-14       Impact factor: 1.738

5.  Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples.

Authors:  Mitchell J Frederick; Amy J VanMeter; Mayur A Gadhikar; Ying C Henderson; Hui Yao; Curtis C Pickering; Michelle D Williams; Adel K El-Naggar; Vlad Sandulache; Emily Tarco; Jeffrey N Myers; Gary L Clayman; Lance A Liotta; Emanuel F Petricoin; Valerie S Calvert; Valentina Fodale; Jing Wang; Randal S Weber
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 6.  Dysregulated molecular networks in head and neck carcinogenesis.

Authors:  Alfredo A Molinolo; Panomwat Amornphimoltham; Cristiane H Squarize; Rogerio M Castilho; Vyomesh Patel; J Silvio Gutkind
Journal:  Oral Oncol       Date:  2008-09-19       Impact factor: 5.337

7.  High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines.

Authors:  Paul A Johnston; Malabika Sen; Yun Hua; Daniel Camarco; Tong Ying Shun; John S Lazo; Jennifer R Grandis
Journal:  Assay Drug Dev Technol       Date:  2013-10-15       Impact factor: 1.738

8.  Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma.

Authors:  Marta Moral; Carmen Segrelles; M Fernanda Lara; Ana Belén Martínez-Cruz; Corina Lorz; Mirentxu Santos; Ramón García-Escudero; Jerry Lu; Kaoru Kiguchi; Agueda Buitrago; Clotilde Costa; Cristina Saiz; Jose L Rodriguez-Peralto; Francisco J Martinez-Tello; Maria Rodriguez-Pinilla; Montserrat Sanchez-Cespedes; Marina Garín; Teresa Grande; Ana Bravo; John DiGiovanni; Jesús M Paramio
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

9.  Dual-inhibitors of STAT5 and STAT3: studies from molecular docking and molecular dynamics simulations.

Authors:  Shengjuan Shao; Rilei Yu; Yanqing Yu; Yanni Li
Journal:  J Mol Model       Date:  2014-08-07       Impact factor: 1.810

10.  LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression.

Authors:  Ja Eun Kim; Hong Sook Kim; Yong Jae Shin; Chang Seok Lee; Cheolhee Won; Sin Ae Lee; Jung Weon Lee; Youngsoo Kim; Jae Seung Kang; Sang Kyu Ye; Myung Hee Chung
Journal:  Exp Mol Med       Date:  2008-10-31       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.